Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106091 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL
A Phase 1 study, sponsored by Affimed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02106091 is a Phase 1 study that was terminated before completion, run by Affimed. The registered enrollment target is 16 participants.
The verdict
NCT02106091, a Phase 1 study, was terminated before completion, sponsored by Affimed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AFM11 is safe and active in the treatment of relapsed and/or refractory Non-Hodgkin Lymphoma (NHL).
Interventions
- DRUG AFM11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106091
The ClinicalTrials.gov registry entry for NCT02106091 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AFM11 is the first listed.
NCT02106091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106091 about?
NCT02106091 is a clinical study titled "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL". The purpose of this study is to determine whether AFM11 is safe and active in the treatment of relapsed and/or refractory Non-Hodgkin Lymphoma (NHL).
What is the current status of trial NCT02106091?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-04. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02106091?
The interventions under investigation include: AFM11 (DRUG).
Who is sponsoring clinical trial NCT02106091?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.